UOB Kay Hian

Stay informed with us

Gain timely investment insights on:

  • Market Views & Allocation
  • Investment Ideas & Opportunities

By subscribing, you agree to receive research insights and marketing communications from us. You may unsubscribe at any time. See our Privacy Policy for details.

Innovent Biologics Inc (1801 HK): 1H26: Results Beat; Set New Revenue Target Of Rmb35b-40b By 2030 | Research | UOB Kay Hian